Published by: RCGP Hot Topics (August 2025)

Original Source: The Lancet, July 2025 – IPD Meta-analysis (n = 28,982)

The RCGP Hot Topics summary explores the key findings from a major 2025 Lancet meta-analysis comparing clopidogrel vs aspirin for secondary prevention in coronary artery disease (CAD). This represents the most robust evidence to date on this topic and may shift long-standing prescribing practices in UK primary care.

At A4Medicine, we've reviewed and simplified the analysis to focus on:

• Key evidence GPs need to know

• AKT-relevant statistics and caveats

• Practical implications for real-world decision-making

Key Clinical Evidence Analysis

Study Design:
Individual Patient Data (IPD) meta-analysis of 7 RCTs (n = 28,982) – Lancet, 2025.

Main Finding:
Clopidogrel monotherapy is superior to aspirin for secondary prevention in established coronary artery disease (CAD), with:

• ↓14% relative risk of major adverse cardiac and cerebrovascular events (MACCE)
  → HR 0.86; p = 0.0082

• No ↑ in major bleeding risk

🧾 Implication: Challenges the traditional "aspirin-first" approach in stable CAD post-DAPT.

Clinical Outcomes: Clopidogrel vs Aspirin for Secondary Prevention of CAD (events per 100 patient-years)

Outcome	Clopidogrel	Aspirin	Absolute Difference
MACCE (CV death, MI, stroke)	2.61	2.99	–0.38
Major Bleeding	0.92	0.94	No significant difference

(Data from The Lancet, 2025)

---

🔍 Supporting Evidence & Validity

• HOST-EXAM Trial: Similar findings in post-PCI patients – ↓ MACCE with clopidogrel

• Subgroup Consistency: Benefit seen across age, sex, diabetes, and renal function groups

• ↑ External Validity: Supports use in diverse UK primary care populations, beyond cardiology settings

UK Primary Care Guidance Context

🧭 NICE TA210 (Current Guidance)

🔄 Mismatch with New Evidence

• The Lancet 2025 meta-analysis suggests clopidogrel may offer superior protection post-MI too — beyond just aspirin intolerance.

• An update to NICE TA210 may be warranted if replicated in further UK-based cohorts.

Key Clinical Messages

• Clopidogrel is more effective than aspirin for secondary prevention in CAD
  → ↓ MACCE by 13% (2.61 vs 2.99 events/100 pt-yrs)

• 
  

• Bleeding risk is equivalent (HR 0.94, p = 0.64)
  → No trade-off in safety for efficacy

• GI bleeding is lower with clopidogrel vs aspirin

• No mortality difference between agents

• 
  

• Genetic variants (CYP2C19) do not impact outcomes in stable CAD
  → Routine genetic testing not required

• 
  

---

🔮 Future Practice Implications

• This is Level 1a evidence and may drive NICE guideline updates, particularly for post-MI care where aspirin remains default

• Clopidogrel may become first-line for all CAD secondary prevention — not just in stroke, PAD, or aspirin intolerance

• 
  

• Cost-effectiveness (despite higher drug cost) likely favourable due to ↓ CV events and hospitalisations

• International shift towards long-term P2Y12 inhibitor use (e.g. clopidogrel) already underway.

AKT Exam Key Takeaways

✔ Know current NICE TA210
 – Stroke/PAD → clopidogrel first-line
 – MI → aspirin still first-line (for now)
 – Multivascular disease → clopidogrel

✔ Recent evidence favours clopidogrel across CAD presentations

✔ Bleeding ≈ same → don’t assume aspirin is safer

✔ No need for CYP2C19 genetic testing before prescribing clopidogrel

✔ Clopidogrel more expensive but cost-effective overall

References

[1](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1265983/full)

[2](https://pubmed.ncbi.nlm.nih.gov/40902613/)

[3](https://www.nice.org.uk/guidance/ta210)

[4](https://gpnotebook.com/en-GB/pages/trauma-medicine/nice-guidance-clopidogrel-and-modified-release-dipyridamole-in-the-prevention-of-occlusive-vascular-events)

[5](https://www.selondonics.org/wp-content/uploads/dlm_uploads/2022/11/ANTIPLATELETS-Summary-of-Options-in-CV-Disease-August-2017.pdf)

[6](https://medicines.necsu.nhs.uk/wp-content/uploads/2015/06/Gateshead-antiplatelet-guidance.pdf)

[7](https://gpnotebook.com/en-IE/pages/cardiovascular-medicine/nice-guidance-antiplatelet-therapy-in-people-with-an-mi-where-there-is-an-indication-for-anticoagulation)

[8](https://en.wikipedia.org/wiki/Clopidogrel)

[9](https://www.lancashireandsouthcumbriammg.nhs.uk/medicines-library/clopidogrel-prevention-occlusive-vascular-events/)

[10](https://medlineplus.gov/druginfo/meds/a601040.html)

[11](https://www.medicines.org.uk/emc/product/5207/smpc)

[12](https://reference.medscape.com/drug/plavix-clopidogrel-342141)

[13](https://nclhealthandcare.org.uk/wp-content/uploads/2023/09/9_Summary_antiplatelets_NCL_CVD.pdf)

[14](https://mot.southyorkshire.icb.nhs.uk/barnsley/files/Barnsley%20Guideline%20for%20using%20Antiplatelet%20drugs%20in%20the%20prevention%20and%20treatment%20of%20Cardiovascular%20and%20Cerebrovascular%20diseases.pdf)

[15](https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/12/33/international-expert-consensus-on-switching-platelet)

[16](https://www.ahajournals.org/doi/10.1161/circulationaha.117.031164)

[17](https://www.nice.org.uk/guidance/ta210/documents/nice-publishes-final-guidance-on-clopidogrel-and-modifiedrelease-dipyridamole-for-the-prevention-of-occlusive-vascular-events3)

[18](https://academic.oup.com/eurheartj/article/45/Supplement_1/ehae666.3348/7838237)

[19](https://www.jacc.org/doi/10.1016/j.jacc.2023.11.004)

[20](https://academic.oup.com/eurheartj/article/44/32/3059/7204812?login=false)

[21](https://academic.oup.com/ehjcvp/article/11/5/451/8104275)

[22](https://pmc.ncbi.nlm.nih.gov/articles/PMC7408729/)

[23](https://gpnotebook.com/pages/cardiovascular-medicine/nice-guidance-clopidogrel-in-nstemi)

[24](https://pmc.ncbi.nlm.nih.gov/articles/PMC11882542/)

[25](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf423/8242428?searchresult=1)

[26](https://www.gloshospitals.nhs.uk/media/documents/Antiplatelet_guideline_0osipmz.pdf)

[27](https://pmc.ncbi.nlm.nih.gov/articles/PMC9303765/)

[28](https://rightdecisions.scot.nhs.uk/media/mwia4qxm/55-antiplatelet-therapy-prescribing-v3.pdf)

[29](https://pmc.ncbi.nlm.nih.gov/articles/PMC6715172/)

[30](https://pmc.ncbi.nlm.nih.gov/articles/PMC9092185/)

[31](https://ccs.ca/wp-content/uploads/2020/11/APT_Gui_2018_PG_EN_web.pdf)

[32](https://www.racgp.org.au/afp/2013/october/dual-antiplatelet-therapy)

[33](https://pmc.ncbi.nlm.nih.gov/articles/PMC9595021/)

[34](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309)

[35](https://geekymedics.com/prescribing-antiplatelet-therapy/)

[36](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1527667/full)

[37](http://www.sefap.it/servizi_lineeguida_201101/52030.pdf)

[38](https://www.ahajournals.org/doi/10.1161/JAHA.118.009856)

[39](https://database.inahta.org/article/32312)

[40](https://best.barnsleyccg.nhs.uk/media/0filj0dh/antiplatelet-guidance.pdf)

[41](https://pmc.ncbi.nlm.nih.gov/articles/PMC10889184/)

[42](https://www.ahajournals.org/doi/10.1161/circ.150.suppl_1.4139258)

[43](https://gpnotebook.com/pages/trauma-medicine/nice-guidance-clopidogrel-and-modified-release-dipyridamole-in-the-prevention-of-occlusive-vascular-events)

[44](https://www.ncbi.nlm.nih.gov/books/NBK470539/)

[45](https://pie.med.utoronto.ca/CVmanual/CVManual_content/assets/2013pdfs/Acute%20Coronary%20Syndromes/Antiplatelet%20Therapy%20Switching%20-%20Clinician%20Guide.pdf)

[46](https://www.youtube.com/watch?v=X1VLcs4ee3M)

[47](https://www.rcgp.org.uk/getmedia/8f99c1ac-7b31-44f8-8eaf-eb0c4174bf07/AKT-Example-Questions-with-answers-February-2025.pdf)

[48](https://www.ahajournals.org/doi/full/10.1161/circulationaha.117.031164?keytype=ref&ijkey=XJdNat4iziwfMzT)

[49](https://gp-training.hee.nhs.uk/cornwall/wp-content/uploads/sites/86/2021/04/RCGP-sample-questions-with-answers.pdf)

[50](https://www.mayoclinic.org/drugs-supplements/clopidogrel-oral-route/description/drg-20063146)

[51](https://pmc.ncbi.nlm.nih.gov/articles/PMC6597198/)

[52](https://madeinheene.hee.nhs.uk/Portals/6/Trainers/Educators%20Conference/2021%20conference%20handouts/MRCGP%20AKT%20questions%20without%20answers.pdf?ver=2021-03-09-092436-253)

[53](https://www.webmd.com/drugs/2/drug-5190/clopidogrel-oral/details)

[54](https://solaci.org/en/2017/11/27/when-and-how-to-switch-dual-antiplatelet-therapies/)

[55](https://nwpgmd.nhs.uk/sites/default/files/AKT%20Study%20Guide%20.pdf)

[56](https://pmc.ncbi.nlm.nih.gov/articles/PMC10199733/)